Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance

Gilead Sciences, Inc.Trade
Norwegian Cruise Line Holdings LtdTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Norwegian Cruise Line Holdings Ltd — how do they compare? Gilead Sciences, Inc. trades at $135.71 (market cap $168.35B), while Norwegian Cruise Line Holdings Ltd trades at $18.92 (market cap $8.59B). The key difference: Gilead Sciences, Inc. is far larger — about 19.6× Norwegian Cruise Line Holdings Ltd's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.

GILDNCLH
Market Cap
$168.35B$8.59B
Sector
HealthConsumer Cyclical
52-Week High
$155.80$26.94
52-Week Low
$110.56$14.79
Enterprise Value
$191.42B$23.40B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.

Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.

Norwegian Cruise Line Holdings Ltd

NCLH trades at $18.93, up 2.05% today, with a bearish technical signal but strong fundamentals including a P/E of 11.33 and net income margin of 7.49%. Recent Q2 2026 earnings beat expectations at $0.48 per share, though revenue growth faces headwinds from high costs. Analyst consensus is a buy with a $20.73 price target, but news highlights concerns over fuel expenses and demand.

The outlook is mixed: valuation metrics suggest upside potential, but risks from macroeconomic pressures and execution challenges persist. Investors may find opportunity if turnaround plans gain traction, yet volatility from operational costs and travel demand fluctuations warrants caution for near-term performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.

Read more on NCLH